Delta Lloyd Asset Management N.V. Buys New Holdings in Bristol-Myers Squibb Company (BMY)

Delta Lloyd Asset Management N.V. bought a new position in Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 178,074 shares of the biopharmaceutical company’s stock, valued at approximately $9,922,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares in the last quarter. Keel Point LLC increased its holdings in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 18 shares during the last quarter. Staley Capital Advisers Inc. increased its holdings in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 24 shares during the last quarter. Shayne & CO. LLC increased its holdings in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 24 shares during the last quarter. Finally, Greenleaf Trust increased its holdings in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 39 shares during the last quarter. 69.82% of the stock is currently owned by institutional investors and hedge funds.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.23% of the stock is owned by insiders.

Bristol-Myers Squibb Company (BMY) traded down $0.77 during trading hours on Monday, hitting $62.47. 4,893,726 shares of the company’s stock traded hands, compared to its average volume of 8,468,353. The firm has a market capitalization of $103,504.91, a P/E ratio of 21.36, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a fifty-two week low of $46.01 and a fifty-two week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the firm posted $0.77 earnings per share. research analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

BMY has been the subject of a number of recent analyst reports. Credit Suisse Group restated a “hold” rating and set a $61.00 price target (up previously from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Cowen restated a “hold” rating and set a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Jefferies Group lifted their target price on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a report on Monday, September 11th. Piper Jaffray Companies reiterated a “hold” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Finally, Leerink Swann lifted their target price on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $64.93.

TRADEMARK VIOLATION NOTICE: “Delta Lloyd Asset Management N.V. Buys New Holdings in Bristol-Myers Squibb Company (BMY)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/04/delta-lloyd-asset-management-n-v-takes-9-92-million-position-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply